Quarterly report [Sections 13 or 15(d)]

Revenues from Contracts and Significant Customers (Company's product revenue) (Details)

v3.25.3
Revenues from Contracts and Significant Customers (Company's product revenue) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenues from Contracts and Significant Customers        
Revenue $ 17,025 $ 14,629 $ 45,173 $ 42,514
Other revenue 606   2,010  
Net revenue 17,631 14,629 47,183 42,555
Emrosi        
Revenues from Contracts and Significant Customers        
Revenue 4,883   9,748  
Qbrexza        
Revenues from Contracts and Significant Customers        
Revenue 7,361 7,583 19,470 19,435
Accutane        
Revenues from Contracts and Significant Customers        
Revenue 2,769 3,996 9,818 15,534
Vyne acquisition products (Amzeeq & Zilxi)        
Revenues from Contracts and Significant Customers        
Revenue 1,311 2,100 3,973 4,703
Other / legacy product revenue        
Revenues from Contracts and Significant Customers        
Revenue $ 701 $ 950 $ 2,164 2,842
Related Party        
Revenues from Contracts and Significant Customers        
Revenue - related party       $ 41